高平均动脉压目标对老年脓毒性休克患者的疗效(OPTPRESS):一项多中心、实用性、开放标签、随机对照试验
该多中心、实用性、开放标签随机对照试验在日本29家医院开展,纳入年龄≥65岁的脓毒性休克ICU患者,1:1随机分为高目标组(目标MAP 80-85 mmHg)和对照组(目标MAP 65-70 mmHg),目标MAP维持72小时或直至不再需要血管升压药。主要终点为90天全因死亡率:高目标组101例(39.3%),对照组74例(28.6%),风险差10.7(95%CI 2.6-18.9)。高目标组28天肾脏替代治疗无天数更短,包括已知慢性高血压患者在内的任何亚组均未观察到临床获益。试验因中期分析提示高目标策略存在伤害而提前终止。
要点
- 老年脓毒性休克患者高目标MAP(80-85 mmHg)较对照(65-70 mmHg)90天全因死亡率更高:39.3% vs 28.6%,风险差10.7(95%CI 2.6-18.9)。
- 高目标组28天肾脏替代治疗无天数较对照组更短。
- 包括已知慢性高血压患者在内的任何亚组均未观察到高目标MAP的临床获益。
- 试验因中期分析提示高目标策略存在伤害而提前终止。
- 研究在日本29家医院开展,当地老年人慢性高血压患病率为66.9%。
适用人群与场景
- 年龄≥65岁、诊断为脓毒性休克并收入ICU的患者。
- 研究在日本29家医院开展,当地老年人慢性高血压患病率为66.9%。
- 随机分组时间为2021年7月1日至2023年12月12日。
诊断标准与关键阈值
- 脓毒性休克诊断:原文仅写「诊断为脓毒性休克」,未列出具体诊断标准。
- 高目标组目标MAP 80-85 mmHg,对照组目标MAP 65-70 mmHg。
- 目标MAP维持72小时或直至不再需要血管升压药。
处置流程与药物剂量
- 将符合条件患者1:1随机分配至高目标组(目标MAP 80-85 mmHg)或对照组(目标MAP 65-70 mmHg)。
- 目标MAP维持72小时或直至不再需要血管升压药。
研究设计与关键结果
- 多中心、实用性、开放标签、随机对照试验,日本29家医院,共518例患者(高目标组258例,对照组260例)。
- 主要终点90天全因死亡率:高目标组101例(39.3%)vs 对照组74例(28.6%),风险差10.7(95%CI 2.6-18.9)。
- 高目标组28天肾脏替代治疗无天数较对照组更短。
- 包括已知慢性高血压患者在内的任何亚组均未观察到临床获益。
- 试验因中期分析提示高目标策略存在伤害而提前终止。
证据类型、等级与局限
- 证据类型:多中心、实用性、开放标签、随机对照试验。
- 试验注册:UMIN Clinical Trials Registry,UMIN000041775,2020年9月13日。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于年龄≥65岁的脓毒性休克ICU患者,将MAP目标设为80-85 mmHg(而非65-70 mmHg)与90天全因死亡率显著升高相关(39.3% vs 28.6%)。
- 高目标MAP组28天肾脏替代治疗无天数更短,提示该策略不增加无肾脏替代治疗天数。
- 包括已知慢性高血压患者在内的任何亚组均未观察到高目标MAP的临床获益。
- 作者结论:在老年脓毒性休克患者中,高目标MAP较标准治疗显著增加死亡率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: We examined the effect of a high-target mean arterial pressure (MAP) on septic shock in a previously underrepresented region.
METHODS: A multicentre, pragmatic, open-label, randomised controlled trial was conducted in 29 hospitals in Japan, where the prevalence of chronic hypertension among older individuals is 66.9%. Patients who were diagnosed with septic shock, aged ≥ 65 years, and admitted to an intensive care unit were randomised 1:1 to the high (target MAP = 80-85 mmHg) or control (target MAP = 65-70 mmHg) groups from 1 July 2021 to 12 December 2023. The target MAP was maintained for 72 h or until vasopressors were no longer required. The primary outcome was the 90-day all-cause mortality. Secondary outcomes included organ support-free days and adverse events.
RESULTS: The trial was terminated early on the basis of the interim analysis results, suggesting the harm of the high-target strategy. Of the 518 patients, 258 were in the high-target group, and 260 were in the control group. By 90 days after randomisation, 101 patients (39.3%) in the high-target group and 74 (28.6%) in the control group had died from any cause (risk difference = 10.7; 95% confidence interval, 2.6-18.9). Renal replacement therapy-free days at 28 days were shorter in the high-target group. No clinical benefits for any outcome were observed in any subpopulation, including those with known chronic hypertension.
CONCLUSION: Among older patients with septic shock, high-target MAP significantly increased mortality compared with standard care.
TRIAL REGISTRATION: UMIN Clinical Trials Registry; UMIN000041775; 13 September 2020.
参考来源
- Endo A, Yamakawa K, Tagami T, et al. Efficacy of targeting high mean arterial pressure for older patients with septic shock (OPTPRESS): a multicentre, pragmatic, open-label, randomised controlled trial. Intensive Care Med. 2025. PMID: 40358717. doi:10.1007/s00134-025-07910-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。